A pilot phase II protocol of arsenic trioxide (Trisenox) in subjects with advanced non-small cell carcinoma of the lung
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2013
At a glance
- Drugs Arsenic trioxide (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2005 New trial record.